Celalettin Ustun to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Celalettin Ustun has written about Leukemia, Myeloid, Acute.
Connection Strength
2.803
-
Transplantation provides superior survival high risk myeloid malignancies in older patients. Leuk Lymphoma. 2022 10; 63(10):2494-2498.
Score: 0.787
-
Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 02; 43(1):e19-e25.
Score: 0.701
-
Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. Blood Adv. 2019 11 26; 3(22):3709-3712.
Score: 0.663
-
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022 01 08; 6(3):828-847.
Score: 0.192
-
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2021 08 01; 106(8):2295-2296.
Score: 0.186
-
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020 05; 105(5):1329-1338.
Score: 0.164
-
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014 Feb; 20(2):202-8.
Score: 0.109